Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of the current coronavirus disease 2019 (COVID‐19) pandemic. Understanding the immune response that provides specific immunity but may also lead to immunopathology is crucial for the design of potential preventive an...
Gespeichert in:
Veröffentlicht in: | European journal of immunology 2020-12, Vol.50 (12), p.1998-2012 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2012 |
---|---|
container_issue | 12 |
container_start_page | 1998 |
container_title | European journal of immunology |
container_volume | 50 |
creator | Oja, Anna E. Saris, Anno Ghandour, Cherien A. Kragten, Natasja A.M. Hogema, Boris M. Nossent, Esther J. Heunks, Leo M.A. Cuvalay, Susan Slot, Ed Linty, Federica Swaneveld, Francis H. Vrielink, Hans Vidarsson, Gestur Rispens, Theo Schoot, Ellen Lier, René A.W. Ten Brinke, Anja Hombrink, Pleun |
description | Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of the current coronavirus disease 2019 (COVID‐19) pandemic. Understanding the immune response that provides specific immunity but may also lead to immunopathology is crucial for the design of potential preventive and therapeutic strategies. Here, we characterized and quantified SARS‐CoV‐2‐specific immune responses in patients with different clinical courses. Compared to individuals with a mild clinical presentation, CD4+ T‐cell responses were qualitatively impaired in critically ill patients. Strikingly, however, in these patients the specific IgG antibody response was remarkably strong. Furthermore, in these critically ill patients, a massive influx of circulating T cells into the lungs was observed, overwhelming the local T‐cell compartment, and indicative of vascular leakage. The observed disparate T‐ and B‐cell responses could be indicative of a deregulated immune response in critically ill COVID‐19 patients.
T‐ and B‐cell responses are misbalanced in critically ill COVID‐19 patients compared to patients with mild or severe symptoms. CD4+ T‐cell responses in these patients are impaired qualitatively and quantitatively. BALF of ICU patients shows an influx of circulating T cells indicative of vascular leakage and lung damage. |
doi_str_mv | 10.1002/eji.202048908 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2452096353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2452096353</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4311-f3949c2c03e4591d86007ff1e6fda5d93d152f391ac9218c549020cdb1b590543</originalsourceid><addsrcrecordid>eNp9kbtOw0AQRVcIBCFQ0qKVaGgMs6_EW0J4BSFF4pHWctZjtJFjG68NouMT-Ea-hIkSKCgoZmdWOrqaO5exAwEnAkCe4tyfSJCgYwvxBusJI0WkhRabrAcgdCRtDDtsN4Q5ANiBsdtsRykYKmVsj80v_Cs2z1i2_OHs_uHr43NUTemVVKFG53Pv-CN9eFpm_JwGh0XBGwx1VQYM3Jc8IEkgn3UtL6uWL3yR8dFkOr4gWlhep60n_bDHtvK0CLi_7n32dHX5OLqJ7ibX49HZXeS0EiLKldXWSQcKtbEiiwcAwzwXOMiz1GRWZWSRIJE6K0XsjLZk32UzMTMWjFZ9drzSrZvqpcPQJgsfllunJVZdSKQ2kg6hjCL06A86r7qmpO2IGliwVmkgKlpRrqlCaDBP6sYv0uY9EZAsQ0gohOQ3BOIP16rdbIHZL_1zdQLkCnjzBb7_r5Zc3o41GVXfyD6T8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2469099340</pqid></control><display><type>article</type><title>Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Oja, Anna E. ; Saris, Anno ; Ghandour, Cherien A. ; Kragten, Natasja A.M. ; Hogema, Boris M. ; Nossent, Esther J. ; Heunks, Leo M.A. ; Cuvalay, Susan ; Slot, Ed ; Linty, Federica ; Swaneveld, Francis H. ; Vrielink, Hans ; Vidarsson, Gestur ; Rispens, Theo ; Schoot, Ellen ; Lier, René A.W. ; Ten Brinke, Anja ; Hombrink, Pleun</creator><creatorcontrib>Oja, Anna E. ; Saris, Anno ; Ghandour, Cherien A. ; Kragten, Natasja A.M. ; Hogema, Boris M. ; Nossent, Esther J. ; Heunks, Leo M.A. ; Cuvalay, Susan ; Slot, Ed ; Linty, Federica ; Swaneveld, Francis H. ; Vrielink, Hans ; Vidarsson, Gestur ; Rispens, Theo ; Schoot, Ellen ; Lier, René A.W. ; Ten Brinke, Anja ; Hombrink, Pleun</creatorcontrib><description>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of the current coronavirus disease 2019 (COVID‐19) pandemic. Understanding the immune response that provides specific immunity but may also lead to immunopathology is crucial for the design of potential preventive and therapeutic strategies. Here, we characterized and quantified SARS‐CoV‐2‐specific immune responses in patients with different clinical courses. Compared to individuals with a mild clinical presentation, CD4+ T‐cell responses were qualitatively impaired in critically ill patients. Strikingly, however, in these patients the specific IgG antibody response was remarkably strong. Furthermore, in these critically ill patients, a massive influx of circulating T cells into the lungs was observed, overwhelming the local T‐cell compartment, and indicative of vascular leakage. The observed disparate T‐ and B‐cell responses could be indicative of a deregulated immune response in critically ill COVID‐19 patients.
T‐ and B‐cell responses are misbalanced in critically ill COVID‐19 patients compared to patients with mild or severe symptoms. CD4+ T‐cell responses in these patients are impaired qualitatively and quantitatively. BALF of ICU patients shows an influx of circulating T cells indicative of vascular leakage and lung damage.</description><identifier>ISSN: 0014-2980</identifier><identifier>EISSN: 1521-4141</identifier><identifier>DOI: 10.1002/eji.202048908</identifier><identifier>PMID: 33073359</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Antibodies, Viral - immunology ; Antibody response ; B-Lymphocytes - immunology ; B-Lymphocytes - pathology ; CD4 antigen ; CD4+ T cells ; CD4-Positive T-Lymphocytes - immunology ; CD4-Positive T-Lymphocytes - pathology ; Coronaviridae ; Coronaviruses ; COVID-19 ; COVID-19 - immunology ; COVID-19 - pathology ; Female ; Humans ; IgG ; Immunoglobulin G ; Immunoglobulin G - immunology ; Lymphocytes T ; Male ; Middle Aged ; Pandemics ; SARS-CoV-2 - immunology ; SARS‐CoV‐2 ; Severe acute respiratory syndrome coronavirus 2 ; Severity of Illness Index</subject><ispartof>European journal of immunology, 2020-12, Vol.50 (12), p.1998-2012</ispartof><rights>2020 Wiley‐VCH GmbH</rights><rights>2020 Wiley-VCH GmbH.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4311-f3949c2c03e4591d86007ff1e6fda5d93d152f391ac9218c549020cdb1b590543</citedby><cites>FETCH-LOGICAL-c4311-f3949c2c03e4591d86007ff1e6fda5d93d152f391ac9218c549020cdb1b590543</cites><orcidid>0000-0002-9433-1630 ; 0000-0001-9600-1312</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Feji.202048908$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Feji.202048908$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33073359$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oja, Anna E.</creatorcontrib><creatorcontrib>Saris, Anno</creatorcontrib><creatorcontrib>Ghandour, Cherien A.</creatorcontrib><creatorcontrib>Kragten, Natasja A.M.</creatorcontrib><creatorcontrib>Hogema, Boris M.</creatorcontrib><creatorcontrib>Nossent, Esther J.</creatorcontrib><creatorcontrib>Heunks, Leo M.A.</creatorcontrib><creatorcontrib>Cuvalay, Susan</creatorcontrib><creatorcontrib>Slot, Ed</creatorcontrib><creatorcontrib>Linty, Federica</creatorcontrib><creatorcontrib>Swaneveld, Francis H.</creatorcontrib><creatorcontrib>Vrielink, Hans</creatorcontrib><creatorcontrib>Vidarsson, Gestur</creatorcontrib><creatorcontrib>Rispens, Theo</creatorcontrib><creatorcontrib>Schoot, Ellen</creatorcontrib><creatorcontrib>Lier, René A.W.</creatorcontrib><creatorcontrib>Ten Brinke, Anja</creatorcontrib><creatorcontrib>Hombrink, Pleun</creatorcontrib><title>Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients</title><title>European journal of immunology</title><addtitle>Eur J Immunol</addtitle><description>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of the current coronavirus disease 2019 (COVID‐19) pandemic. Understanding the immune response that provides specific immunity but may also lead to immunopathology is crucial for the design of potential preventive and therapeutic strategies. Here, we characterized and quantified SARS‐CoV‐2‐specific immune responses in patients with different clinical courses. Compared to individuals with a mild clinical presentation, CD4+ T‐cell responses were qualitatively impaired in critically ill patients. Strikingly, however, in these patients the specific IgG antibody response was remarkably strong. Furthermore, in these critically ill patients, a massive influx of circulating T cells into the lungs was observed, overwhelming the local T‐cell compartment, and indicative of vascular leakage. The observed disparate T‐ and B‐cell responses could be indicative of a deregulated immune response in critically ill COVID‐19 patients.
T‐ and B‐cell responses are misbalanced in critically ill COVID‐19 patients compared to patients with mild or severe symptoms. CD4+ T‐cell responses in these patients are impaired qualitatively and quantitatively. BALF of ICU patients shows an influx of circulating T cells indicative of vascular leakage and lung damage.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Viral - immunology</subject><subject>Antibody response</subject><subject>B-Lymphocytes - immunology</subject><subject>B-Lymphocytes - pathology</subject><subject>CD4 antigen</subject><subject>CD4+ T cells</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD4-Positive T-Lymphocytes - pathology</subject><subject>Coronaviridae</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>IgG</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - immunology</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pandemics</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS‐CoV‐2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Severity of Illness Index</subject><issn>0014-2980</issn><issn>1521-4141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kbtOw0AQRVcIBCFQ0qKVaGgMs6_EW0J4BSFF4pHWctZjtJFjG68NouMT-Ea-hIkSKCgoZmdWOrqaO5exAwEnAkCe4tyfSJCgYwvxBusJI0WkhRabrAcgdCRtDDtsN4Q5ANiBsdtsRykYKmVsj80v_Cs2z1i2_OHs_uHr43NUTemVVKFG53Pv-CN9eFpm_JwGh0XBGwx1VQYM3Jc8IEkgn3UtL6uWL3yR8dFkOr4gWlhep60n_bDHtvK0CLi_7n32dHX5OLqJ7ibX49HZXeS0EiLKldXWSQcKtbEiiwcAwzwXOMiz1GRWZWSRIJE6K0XsjLZk32UzMTMWjFZ9drzSrZvqpcPQJgsfllunJVZdSKQ2kg6hjCL06A86r7qmpO2IGliwVmkgKlpRrqlCaDBP6sYv0uY9EZAsQ0gohOQ3BOIP16rdbIHZL_1zdQLkCnjzBb7_r5Zc3o41GVXfyD6T8Q</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Oja, Anna E.</creator><creator>Saris, Anno</creator><creator>Ghandour, Cherien A.</creator><creator>Kragten, Natasja A.M.</creator><creator>Hogema, Boris M.</creator><creator>Nossent, Esther J.</creator><creator>Heunks, Leo M.A.</creator><creator>Cuvalay, Susan</creator><creator>Slot, Ed</creator><creator>Linty, Federica</creator><creator>Swaneveld, Francis H.</creator><creator>Vrielink, Hans</creator><creator>Vidarsson, Gestur</creator><creator>Rispens, Theo</creator><creator>Schoot, Ellen</creator><creator>Lier, René A.W.</creator><creator>Ten Brinke, Anja</creator><creator>Hombrink, Pleun</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9433-1630</orcidid><orcidid>https://orcid.org/0000-0001-9600-1312</orcidid></search><sort><creationdate>202012</creationdate><title>Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients</title><author>Oja, Anna E. ; Saris, Anno ; Ghandour, Cherien A. ; Kragten, Natasja A.M. ; Hogema, Boris M. ; Nossent, Esther J. ; Heunks, Leo M.A. ; Cuvalay, Susan ; Slot, Ed ; Linty, Federica ; Swaneveld, Francis H. ; Vrielink, Hans ; Vidarsson, Gestur ; Rispens, Theo ; Schoot, Ellen ; Lier, René A.W. ; Ten Brinke, Anja ; Hombrink, Pleun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4311-f3949c2c03e4591d86007ff1e6fda5d93d152f391ac9218c549020cdb1b590543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Viral - immunology</topic><topic>Antibody response</topic><topic>B-Lymphocytes - immunology</topic><topic>B-Lymphocytes - pathology</topic><topic>CD4 antigen</topic><topic>CD4+ T cells</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD4-Positive T-Lymphocytes - pathology</topic><topic>Coronaviridae</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>IgG</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - immunology</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pandemics</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS‐CoV‐2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oja, Anna E.</creatorcontrib><creatorcontrib>Saris, Anno</creatorcontrib><creatorcontrib>Ghandour, Cherien A.</creatorcontrib><creatorcontrib>Kragten, Natasja A.M.</creatorcontrib><creatorcontrib>Hogema, Boris M.</creatorcontrib><creatorcontrib>Nossent, Esther J.</creatorcontrib><creatorcontrib>Heunks, Leo M.A.</creatorcontrib><creatorcontrib>Cuvalay, Susan</creatorcontrib><creatorcontrib>Slot, Ed</creatorcontrib><creatorcontrib>Linty, Federica</creatorcontrib><creatorcontrib>Swaneveld, Francis H.</creatorcontrib><creatorcontrib>Vrielink, Hans</creatorcontrib><creatorcontrib>Vidarsson, Gestur</creatorcontrib><creatorcontrib>Rispens, Theo</creatorcontrib><creatorcontrib>Schoot, Ellen</creatorcontrib><creatorcontrib>Lier, René A.W.</creatorcontrib><creatorcontrib>Ten Brinke, Anja</creatorcontrib><creatorcontrib>Hombrink, Pleun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oja, Anna E.</au><au>Saris, Anno</au><au>Ghandour, Cherien A.</au><au>Kragten, Natasja A.M.</au><au>Hogema, Boris M.</au><au>Nossent, Esther J.</au><au>Heunks, Leo M.A.</au><au>Cuvalay, Susan</au><au>Slot, Ed</au><au>Linty, Federica</au><au>Swaneveld, Francis H.</au><au>Vrielink, Hans</au><au>Vidarsson, Gestur</au><au>Rispens, Theo</au><au>Schoot, Ellen</au><au>Lier, René A.W.</au><au>Ten Brinke, Anja</au><au>Hombrink, Pleun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients</atitle><jtitle>European journal of immunology</jtitle><addtitle>Eur J Immunol</addtitle><date>2020-12</date><risdate>2020</risdate><volume>50</volume><issue>12</issue><spage>1998</spage><epage>2012</epage><pages>1998-2012</pages><issn>0014-2980</issn><eissn>1521-4141</eissn><abstract>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of the current coronavirus disease 2019 (COVID‐19) pandemic. Understanding the immune response that provides specific immunity but may also lead to immunopathology is crucial for the design of potential preventive and therapeutic strategies. Here, we characterized and quantified SARS‐CoV‐2‐specific immune responses in patients with different clinical courses. Compared to individuals with a mild clinical presentation, CD4+ T‐cell responses were qualitatively impaired in critically ill patients. Strikingly, however, in these patients the specific IgG antibody response was remarkably strong. Furthermore, in these critically ill patients, a massive influx of circulating T cells into the lungs was observed, overwhelming the local T‐cell compartment, and indicative of vascular leakage. The observed disparate T‐ and B‐cell responses could be indicative of a deregulated immune response in critically ill COVID‐19 patients.
T‐ and B‐cell responses are misbalanced in critically ill COVID‐19 patients compared to patients with mild or severe symptoms. CD4+ T‐cell responses in these patients are impaired qualitatively and quantitatively. BALF of ICU patients shows an influx of circulating T cells indicative of vascular leakage and lung damage.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33073359</pmid><doi>10.1002/eji.202048908</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-9433-1630</orcidid><orcidid>https://orcid.org/0000-0001-9600-1312</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2980 |
ispartof | European journal of immunology, 2020-12, Vol.50 (12), p.1998-2012 |
issn | 0014-2980 1521-4141 |
language | eng |
recordid | cdi_proquest_miscellaneous_2452096353 |
source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
subjects | Adult Aged Antibodies, Viral - immunology Antibody response B-Lymphocytes - immunology B-Lymphocytes - pathology CD4 antigen CD4+ T cells CD4-Positive T-Lymphocytes - immunology CD4-Positive T-Lymphocytes - pathology Coronaviridae Coronaviruses COVID-19 COVID-19 - immunology COVID-19 - pathology Female Humans IgG Immunoglobulin G Immunoglobulin G - immunology Lymphocytes T Male Middle Aged Pandemics SARS-CoV-2 - immunology SARS‐CoV‐2 Severe acute respiratory syndrome coronavirus 2 Severity of Illness Index |
title | Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T05%3A12%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Divergent%20SARS%E2%80%90CoV%E2%80%902%E2%80%90specific%20T%E2%80%90%20and%20B%E2%80%90cell%20responses%20in%20severe%20but%20not%20mild%20COVID%E2%80%9019%20patients&rft.jtitle=European%20journal%20of%20immunology&rft.au=Oja,%20Anna%20E.&rft.date=2020-12&rft.volume=50&rft.issue=12&rft.spage=1998&rft.epage=2012&rft.pages=1998-2012&rft.issn=0014-2980&rft.eissn=1521-4141&rft_id=info:doi/10.1002/eji.202048908&rft_dat=%3Cproquest_cross%3E2452096353%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2469099340&rft_id=info:pmid/33073359&rfr_iscdi=true |